Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today presented additional data showcasing the SANRECO Phase 1 study of divesiran in patients with polycythemia vera (PV) at the European Hematology Association (EHA) 2025 Annual Meeting in Milan, Italy. “The latest data presented at EHA today continue to demonstrate divesiran’s potential to maintain rapid and dur